Home World News FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and...

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

July 18, 2025

847

Evidence for efficacy is based on the results from the KEYNOTE-689 study